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COVID-19 and selective 
vulnerability to 
Parkinson’s disease
The current COVID-19 pandemic 
pro vides a unique opportunity to 
investi gate the hypothesis that viral 
infections can precipitate neuro-
degeneration. Severe acute respiratory 
syndrome coronavirus 1 (SARS-
CoV-1), a pathogenic homolog of 
severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), invades 
the brain through ACE2,1 and SARS-
CoV-2 might be neurotropic too. SARS-
CoV-2 also enters cells via the ACE2 
receptor,1 which is widely expressed 
in the CNS, including in the striatum,2 
where the virus might precipitate 
or accelerate neurodegeneration.3,4 
SARS-CoV-2 might infiltrate the 
CNS directly through the olfactory or 
vagus nerves, or haematogenously. 
This infection could, in turn, prompt 
cyto toxic aggregation of proteins, 
including α-synuclein. This hypothesis 
is supported by evidence in animal 
models that viral infections can trigger 
α-synucleinopathies in the CNS.5
We suspect that neuronal popula-
tions are not equally susceptible to 
degeneration, and that dopaminergic 
neurons are selectively vulnerable 
because of their intrinsic proper ties. For 
instance, high bioenergetic demands 
from highly arborised axons, and 
impaired proteostasis result ing from 
large axon size, can pro mote α-synuclein 
aggregation and result in selective 
vulnerability to non-cell autonomous 
factors that promote α-synuclein seed-
ing, such as neuro inflam mation and 
environmental neurotoxins.
α-Synuclein could function as a 
native antiviral factor within neurons, 
as shown by an increased neuronal 
expression of α-synuclein following 
acute West Nile virus infection.6 West 
Nile virus and SARS-CoV-1 are both 
enveloped, single-stranded, positive 
sense RNA viruses with analogous 
viral entry and replication mechan-
isms.1,6 Therefore, similar α-synuclein 
upregula tion might occur with SARS-
CoV-2 infection. The consequences 
of this pathol ogical process could be 
further exacerbated by a peripheral 
inflam matory response, as occurs in 
COVID-19. A rodent model of peri-
pheral H5N1 influenza infection 
showed persistent CNS microglial 
acti vation and abnormal α-synuclein 
phosphorylation, associated with a 
loss of dopaminergic neurons in the 
substantia nigra pars compacta.7 We 
postulate that antiviral α-synuclein 
accumulation following SARS-CoV-2 
infection might compound pre-
existing cell-autonomous vulnerability 
and lead to α-synuclein propagation 
and widespread neurodegeneration. 
Prospective longitudinal studies in 
survivors of COVID-19 can help to 
support this hypothesis.
SARS-CoV-2 infection might also 
interfere with α-synuclein clearance. 
Other neurotropic viruses, such as 
H1N1 influenza, can obstruct protein 
clearance to maintain optimal viral 
protein levels, rendering infected 
host cells unable to counterbalance 
α-synuclein accumulation.8 SARS-
CoV-2 proteins are capable of binding 
human protein trafficking molecules.9 
One such protein in particular, ORF8, 
is specifically involved in endoplasmic 
reticulum regulation.9 If SARS-CoV-2 
can impair proteostasis through 
ORF8 binding and cause dysregu-
lated endoplasmic reticulum protein 
traffick ing, then α-synuclein could 
aggregate uncontrollably.
Finally, the bioenergetic stress 
of SARS-CoV-2 neuroinvasion might 
be insurmountable for certain neu-
ronal populations. Nigrostriatal dopa-
minergic neurons display high cellular 
energy requirements to fuel elevated 
basal oxidative phosphorylation in 
the mitochondria, high axon term inal 
density, and extensive axonal arborisa-
tion. Considering this large metabolic 
energy use, if addi tional cellular energy 
reserves are unavailable, the cellular 
stress of COVID-19 infection might 
drive these vulnerable neurons over the 
threshold of neurodegeneration.
COVID-19 in older 
people with cognitive 
impairment in 
Latin America
The COVID-19 pandemic in Latin 
America and Caribbean countries (LACs) 
has failed to capture the attention 
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exiguous.7 Many hospitals in LACs have 
inadequate protective equipment and 
there is scarce support for health-care 
workers who become sick.8
Barriers to telemedicine, such as 
restricted internet access, cause addi-
tional complications,4 with around 
40% of hospitals not providing remote 
consultations.8 Certainly, LACs are far 
from uniform, and some cities with 
stronger health systems and resources 
might be able to meet the needs of 
people with demen tia better than 
others. Here, we put forth an urgent 
plea for an international coalition to 
address issues related to dementia 
care in LACs. Regional cooperation 
and shared experi ence cannot be 
ignored in these difficult times. Brain 
health diplomacy, potentially led by 
multi regional non-governmental org-
anisations devoted to dementia, in 
partnership with local institu tions 
should coordinate an action plan.
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implemented control measures, is 
third highest among LACs. The public 
health conditions in these countries are 
complex and pose unique challenges; 
one underlying explanation for the 
surge in cases might be a large informal 
economy, in which workers need to 
leave their house every day to clean 
other households or to stand, for 
instance, at crowded traffic corners 
to sell their goods or shine shoes. 
According to the World Economic 
Forum, about 55% of all workers in 
LACs toil in the informal economy,3 
which amounts to nearly 140 million 
people. Physical distancing in the 
informal economy can be tantamount 
to starvation.
Other explanations point to econo-
mic inequality and inadequate public 
health systems4 but fail to men tion 
the near absence of long-term care 
facilities and programmes for the 
cog ni tively impaired. Dementia care 
differs from standard medical care in 
that caring for dementia must involve 
support for daily activities. Few long-
term care centres exist in LACs. Millions 
populate densely packed favelas or 
barrios, in which large families often 
share a single room, and many find 
moving a grandparent to a nursing 
home inconceiv able. However, older 
people cannot be quarantined within 
crowded living quarters, where they 
can be exposed to young asympto matic 
carriers, and older people who live 
alone struggle to access care without 
risking contact with infected individ-
uals (figure). Extended families that 
ordinarily create a protective environ-
ment and pro vide informal care5 can 
engender environments that increase 
mental health problems and domes-
tic abuse.6
The situation with professional 
health workers provides little solace. 
Weak health-care systems have 
contributed to the already enormous 
toll in mor tality in health-care work-
ers. For instance, with 20% of over 
11 000 health workers in Mexico ill 
with COVID-19—one of the highest 
rates in the world—hospital staffing is 
and attract the resources necessary 
to control it. The wrenching choice 
between public health and economic 
welfare that has polarised political 
debate in the USA and Europe is 
starker in LACs, where older people and 
people with dementia are especially 
susceptible. We want to raise awareness 
about this grave situation.
The population in LACs tripled 
between 1950 and 2000. Although 
LAC populations are still young com-
pared with the USA and western 
Europe, the rate of ageing is among the 
highest in the world.1 This pattern of 
ageing is seen in nearly every country 
in the region,2 with a shift in dependant 
popu lations from young children to 
older relatives.2 Conditions such as 
obesity, hypertension, diabetes, and 
elevated cholesterol, which increase the 
risk of mortality from COVID-19, have 
become more prevalent.
The first patient with confirmed 
COVID-19 was diagnosed in February, 
2020 (a 61-year-old man in São Paulo, 
Brazil). In a few weeks, Brazil surged 
into the top ranks of the most affec-
ted countries. Peru quickly closed its 
borders in March, 2020, and imposed 
rigorous quarantine measures. How-
ever, 4 months later, Peru now has 
the second highest number of con-
firmed cases in LACs. Chile, which also 
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Figure: An elderly man walks through a district in 
Lima, Peru, that is heavily infected with COVID-19
Alejandro, who is 83 years old and has arthrosis, 
using his walker through a crowded market in 
San Juan de Lurigancho, a heavily COVID-19-infected 
district in Lima, Peru. Alejandro lives alone and goes 
out to get food and medicines. He has symptoms 
associated with depression and cognitive decline but 
has no access to neurological care. Photo and 
testimony courtesy of Alexander Kornhuber and 
Maritza Pintado Caipa.
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